1. Home
  2. NDRA vs MYNZ Comparison

NDRA vs MYNZ Comparison

Compare NDRA & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ENDRA Life Sciences Inc.

NDRA

ENDRA Life Sciences Inc.

HOLD

Current Price

$3.82

Market Cap

4.4M

Sector

Health Care

ML Signal

HOLD

Logo Mainz Biomed N.V.

MYNZ

Mainz Biomed N.V.

HOLD

Current Price

$0.83

Market Cap

5.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NDRA
MYNZ
Founded
2007
2021
Country
United States
Germany
Employees
N/A
N/A
Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.4M
5.4M
IPO Year
2016
2021

Fundamental Metrics

Financial Performance
Metric
NDRA
MYNZ
Price
$3.82
$0.83
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$30.00
N/A
AVG Volume (30 Days)
157.4K
260.9K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
97.94
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$5.03
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.92
$0.55
52 Week High
$11.91
$5.61

Technical Indicators

Market Signals
Indicator
NDRA
MYNZ
Relative Strength Index (RSI) 46.06 48.80
Support Level $3.17 $0.57
Resistance Level $4.76 $1.69
Average True Range (ATR) 0.48 0.09
MACD 0.07 0.02
Stochastic Oscillator 18.13 83.89

Price Performance

Historical Comparison
NDRA
MYNZ

About NDRA ENDRA Life Sciences Inc.

ENDRA Life Sciences Inc is engaged in the development of Thermo Acoustic Enhanced UltraSound (TAEUS) to visualize tissue like MRI at the cost and at the point of patient care. TAEUS is designed to work in concert with around 400,000 cart-based ultrasound systems in use globally today. TAEUS is initially focused on the measurement of fat in the liver as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), chronic liver conditions that affect over one billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, the firm is exploring several other clinical applications of TAEUS, including visualization of tissue temperature during energy-based surgical procedures.

About MYNZ Mainz Biomed N.V.

Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.

Share on Social Networks: